Literature DB >> 15980055

Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis.

Stefano Fiorucci1, Giovanni Rizzo, Elisabetta Antonelli, Barbara Renga, Andrea Mencarelli, Luisa Riccardi, Antonio Morelli, Mark Pruzanski, Roberto Pellicciari.   

Abstract

The nuclear receptors farnesoid X receptor (FXR) and peroxisome proliferator-activated receptor (PPAR)gamma exert counter-regulatory effects on hepatic stellate cells (HSCs) and protect against liver fibrosis development in rodents. Here, we investigated whether FXR ligands regulate PPARgamma expression in HSCs and models of liver fibrosis induced in rats by porcine serum and carbon tetrachloride administration and bile duct ligation. Our results demonstrate that HSCs trans-differentiation associated with suppression of PPARgamma mRNA expression, whereas FXR mRNA was unchanged. Exposure of cells to natural and synthetic ligands of FXR, including 6-ethyl chenodeoxycholic acid (6-ECDCA), a synthetic derivative of chenodeoxycholic acid, reversed this effect and increased PPARgamma mRNA by approximately 40-fold. Submaximally effective concentrations of FXR and PPARgamma ligands were additive in inhibiting alpha1(I) collagen mRNA accumulation induced by transforming growth factor (TGF)beta1. Administration of 6-ECDCA in rats rendered cirrhotic by porcine serum and carbon tetrachloride administration or bile duct ligation reverted down-regulation of PPARgamma mRNA expression in HSCs. Cotreatment with 6-ECDCA potentiates the antifibrotic activity of rosiglitazone, a PPARgamma ligand, in the porcine serum model as measured by morphometric analysis of liver collagen content, hydroxyproline, and liver expression of alpha1(I) collagen mRNA, alpha-smooth muscle actin, fibronectin, TGFbeta1, and tissue inhibitor of metalloprotease 1 and 2, whereas it enhanced the expression of PPARgamma and uncoupling protein 2, a PPARgamma-regulated gene, by 2-fold. In conclusion, by using an in vitro and in vivo approach, we demonstrated that FXR ligands up-regulate PPARgamma mRNA in HSCs and in rodent models of liver fibrosis. A FXR-PPARgamma cascade exerts counter-regulatory effects in HSCs activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15980055     DOI: 10.1124/jpet.105.085597

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  53 in total

1.  Roles of microRNA-29a in the antifibrotic effect of farnesoid X receptor in hepatic stellate cells.

Authors:  Jiang Li; Yifei Zhang; Ramalinga Kuruba; Xiang Gao; Chandrashekhar R Gandhi; Wen Xie; Song Li
Journal:  Mol Pharmacol       Date:  2011-04-21       Impact factor: 4.436

Review 2.  Primary biliary cirrhosis: From bench to bedside.

Authors:  Elias Kouroumalis; George Notas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-08-06

Review 3.  Involvement of PPAR nuclear receptors in tissue injury and wound repair.

Authors:  Liliane Michalik; Walter Wahli
Journal:  J Clin Invest       Date:  2006-03       Impact factor: 14.808

Review 4.  Peroxisome proliferator-activated receptors ligands and ischemia-reperfusion injury.

Authors:  Rosanna Di Paola; Salvatore Cuzzocrea
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-03-13       Impact factor: 3.000

Review 5.  Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress.

Authors:  Balasubramaniyan Vairappan
Journal:  World J Hepatol       Date:  2015-03-27

6.  Tubulin alpha 8 is expressed in hepatic stellate cells and is induced in transformed hepatocytes.

Authors:  Lisa Rein-Fischboeck; Rebekka Pohl; Elisabeth M Haberl; Sebastian Zimny; Maximilian Neumann; Kristina Eisinger; Thomas S Weiss; Sabrina Krautbauer; Christa Buechler
Journal:  Mol Cell Biochem       Date:  2017-01-07       Impact factor: 3.396

7.  Direct and Indirect Effects of Fibroblast Growth Factor (FGF) 15 and FGF19 on Liver Fibrosis Development.

Authors:  Justin D Schumacher; Bo Kong; Jason Wu; Daniel Rizzolo; Laura E Armstrong; Monica D Chow; Michael Goedken; Yi-Horng Lee; Grace L Guo
Journal:  Hepatology       Date:  2019-08-09       Impact factor: 17.425

Review 8.  Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis.

Authors:  Justin D Schumacher; Grace L Guo
Journal:  Handb Exp Pharmacol       Date:  2019

9.  Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy.

Authors:  Angela Douglass; Karen Wallace; Matthew Koruth; Caroline Barelle; Andrew J Porter; Matthew C Wright
Journal:  Hepatol Int       Date:  2008-09-03       Impact factor: 6.047

Review 10.  Advances in antifibrotic therapy.

Authors:  Zahra Ghiassi-Nejad; Scott L Friedman
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2008-12       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.